Our results showed that rescue of shRNA‐resistant wild‐type METTL3, but not catalytic mutant METTL3, sensitizes METTL3‐knockdown HCC cells (Fig 2G and H) and sorafenib‐resistant HepG‐2 cells (Fig 2I) to sorafenib treatment. Here, METTL3 is linked to hepatocellular carcinoma.